{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T17:08:49Z","timestamp":1784135329623,"version":"3.55.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003593","name":"CNPq","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"FAPESP","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.thromres.2026.109767","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T16:17:36Z","timestamp":1782317856000},"page":"109767","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Comparative effectiveness and safety of rituximab and caplacizumab for immuno-mediated Thrombotic Thrombocytopenic Purpura: an overview of systematic reviews"],"prefix":"10.1016","volume":"263","author":[{"given":"Mayra","family":"Carvalho-Ribeiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila","family":"Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tha\u00eds D.R.","family":"N\u00f3brega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00edlia Berlofa","family":"Visacri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda A.","family":"Orsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.thromres.2026.109767_bb0005","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/bloodadvances.2017005124","article-title":"Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015","volume":"1","author":"Page","year":"2017","journal-title":"Blood Adv."},{"issue":"6","key":"10.1016\/j.thromres.2026.109767_bb0010","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura","volume":"325","author":"Rock","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2026.109767_bb0015","author":"National Health System"},{"key":"10.1016\/j.thromres.2026.109767_bb0020","doi-asserted-by":"crossref","unstructured":"Zheng XL, Vesely SK, Cataland SR, Coppo P, Geldziler B, Iorio A, et al. ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. J. Thromb. Haemost. 2020 Oct;18(10):2496\u2013502. doi:https:\/\/doi.org\/10.1111\/jth.15010.","DOI":"10.1111\/jth.15010"},{"key":"10.1016\/j.thromres.2026.109767_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.thromres.2026.109590","article-title":"Brazilian Registry of Thrombotic Thrombocytopenic Purpura: a prospective cohort study of diagnosis, management and outcomes in Brazil","volume":"258","author":"N\u00f3brega","year":"2026","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2026.109767_bb0030","series-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane","article-title":"Chapter V: Overviews of Reviews [last updated August 2023]","author":"Pollock","year":"2024"},{"key":"10.1016\/j.thromres.2026.109767_bb0035","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-070849","article-title":"Reporting guideline for overviews of reviews of healthcare interventions: development of the PRIOR statement","volume":"378","author":"Gates","year":"2022","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.thromres.2026.109767_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst. Rev."},{"key":"10.1016\/j.thromres.2026.109767_bb0045","doi-asserted-by":"crossref","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"258","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.thromres.2026.109767_bb0050","doi-asserted-by":"crossref","DOI":"10.1177\/1076029618825309","article-title":"Comparison of the long-term remission of rituximab and conventional treatment for acquired thrombotic thrombocytopenic purpura: a systematic review and meta-analysis","volume":"25","author":"Owattanapanich","year":"2019","journal-title":"Clin. Appl. Thromb."},{"key":"10.1016\/j.thromres.2026.109767_bb0055","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ejim.2024.12.027","article-title":"Rituximab in Immune-mediated thrombotic thrombocytopenic purpura","volume":"135","author":"Li","year":"2025","journal-title":"Eur. J. Intern. Med."},{"issue":"12","key":"10.1016\/j.thromres.2026.109767_bb0060","doi-asserted-by":"crossref","first-page":"657","DOI":"10.21037\/atm-22-2847","article-title":"Comparison of the efficacy and safety of caplacizumab versus placebo in thrombotic thrombocytopenic purpura: a meta-analysis and systematic review based on randomized controlled trials","volume":"10","author":"Chen","year":"2022","journal-title":"Ann. Transl. Med."},{"issue":"10","key":"10.1016\/j.thromres.2026.109767_bb0065","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1182\/bloodadvances.2022008443","article-title":"Adding caplacizumab to standard of care in thrombotic thrombocytopenic purpura: a systematic review and meta-analysis","volume":"7","author":"Djulbegovic","year":"2023","journal-title":"Blood Adv."},{"issue":"5","key":"10.1016\/j.thromres.2026.109767_bb0070","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/17474086.2023.2202850","article-title":"Efficacy and safety of caplacizumab in the treatment of thrombotic thrombocytopenic purpura: a systematic review and meta-analysis","volume":"16","author":"He","year":"2023","journal-title":"Expert Rev. Hematol."},{"issue":"1","key":"10.1016\/j.thromres.2026.109767_bb0075","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/jha2.833","volume":"5","author":"Neupane","year":"2024","journal-title":"eJHaem"},{"issue":"5","key":"10.1016\/j.thromres.2026.109767_bb0080","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/MBC.0000000000001313","article-title":"Efficacy and relative safety of caplacizumab in immune-mediated thrombotic thrombocytopenic purpura: a systematic review and meta-analysis","volume":"35","author":"Peng","year":"2024","journal-title":"Blood Coagul. Fibrinolysis"},{"issue":"7","key":"10.1016\/j.thromres.2026.109767_bb0085","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/blood-2011-03-341131","article-title":"A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura","volume":"118","author":"Scully","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.thromres.2026.109767_bb0090","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/CCM.0b013e31822e9d66","article-title":"Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center","volume":"40","author":"Froissart","year":"2012","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.thromres.2026.109767_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/195746","article-title":"Approach to management of thrombotic thrombocytopenic purpura at University of Cincinnati","volume":"2013","author":"Abdel Karim","year":"2013","journal-title":"Adv. Hematol."},{"issue":"24","key":"10.1016\/j.thromres.2026.109767_bb0100","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1182\/blood-2016-03-703827","article-title":"Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura","volume":"127","author":"Page","year":"2016","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.thromres.2026.109767_bb0105","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1111\/trf.14193","article-title":"Rituximab for thrombotic thrombocytopenic purpura: lessons from the STAR trial","volume":"57","author":"Uhl","year":"2017","journal-title":"Transfusion (Paris)"},{"issue":"10","key":"10.1016\/j.thromres.2026.109767_bb0110","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1055\/s-0038-1668545","article-title":"Relapse rate in survivors of acute autoimmune thrombotic thrombocytopenic purpura treated with or without rituximab","volume":"118","author":"Falter","year":"2018","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2026.109767_bb0115","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2020.588526","article-title":"Outcomes of immune thrombotic thrombocytopenic purpura (iTTP) with upfront cyclophosphamide vs. rituximab","volume":"7","author":"Abou-Ismail","year":"2020","journal-title":"Front. Med."},{"issue":"6","key":"10.1016\/j.thromres.2026.109767_bb0120","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1007\/s12185-020-02974-y","article-title":"Rituximab prolongs the time to relapse in patients with immune thrombotic thrombocytopenic purpura: analysis of off-label use in Japan","volume":"112","author":"Kubo","year":"2020","journal-title":"Int. J. Hematol."},{"issue":"2","key":"10.1016\/j.thromres.2026.109767_bb0125","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1182\/blood-2014-01-550244","article-title":"Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura","volume":"124","author":"Hie","year":"2014","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.thromres.2026.109767_bb0130","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1182\/blood-2018-04-840090","article-title":"Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura","volume":"132","author":"Jestin","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.thromres.2026.109767_bb0135","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1159\/000371867","article-title":"A 14-year experience in the management of patients with acquired immune thrombotic thrombocytopenic purpura in northern Israel","volume":"134","author":"Rinott","year":"2015","journal-title":"Acta Haematol."},{"issue":"4","key":"10.1016\/j.thromres.2026.109767_bb0140","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.thromres.2026.109767_bb0145","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"Supplement_3","key":"10.1016\/j.thromres.2026.109767_bb0150","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfaa142.P0202","article-title":"P0202 firts real-life data of patients treated for thrombotic thrombocytopenic purpura from the French thrombotic microangiopathies network","volume":"35","author":"Maanaoui","year":"2020","journal-title":"Nephrol. Dial. Transplant."},{"issue":"13","key":"10.1016\/j.thromres.2026.109767_bb0155","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1182\/blood.2020007599","article-title":"Real-world experience with caplacizumab in the management of acute TTP","volume":"137","author":"Dutt","year":"2021","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.thromres.2026.109767_bb0160","doi-asserted-by":"crossref","first-page":"6219","DOI":"10.1182\/bloodadvances.2022008028","article-title":"Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura","volume":"6","author":"Izquierdo","year":"2022","journal-title":"Blood Adv."},{"issue":"Supplement 1","key":"10.1016\/j.thromres.2026.109767_bb0165","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1182\/blood-2020-142987","article-title":"Real-world data with the use of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura (aTTP)","volume":"136","author":"Jimenez","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2026.109767_bb0170","first-page":"752","article-title":"Caplacizumab induces fast and durable platelet count responses with improved time to complete remission and recurrence-free survival in patients with acquired thrombotic thrombocytopenic purpura","volume":"4","author":"Coppo","year":"2020","journal-title":"Hemasphere"},{"key":"10.1016\/j.thromres.2026.109767_bb0175","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2022018847","article-title":"Delayed normalisation of ADAMTS13 activity in acute Thrombotic Thrombocytopenic Purpura in the caplacizumab era","author":"Prasannan","year":"2023","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.thromres.2026.109767_bb0180","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jtha.2022.11.010","article-title":"Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura","volume":"21","author":"V\u00f6lker","year":"2023","journal-title":"J. Thromb. Haemost."},{"issue":"13","key":"10.1016\/j.thromres.2026.109767_bb0185","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1182\/bloodadvances.2020001973","article-title":"Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura","volume":"4","author":"V\u00f6lker","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.thromres.2026.109767_bb0190","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1226114","article-title":"Caplacizumab for immune thrombotic thrombocytopenic purpura: real-world multicenter data","volume":"10","author":"Gavriilaki","year":"2023","journal-title":"Front. Med."},{"issue":"14","key":"10.1016\/j.thromres.2026.109767_bb0195","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/blood.2020009150","article-title":"Redefining outcomes in immune TTP: an international working group consensus report","volume":"137","author":"Cuker","year":"2021","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.thromres.2026.109767_bb0200","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1182\/blood.2024026390","article-title":"Impact of new medications on the treatment of immune TTP","volume":"145","author":"Scully","year":"2025","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.thromres.2026.109767_bb0205","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1056\/NEJMoa2402567","article-title":"Recombinant ADAMTS13 for Immune Thrombotic Thrombocytopenic Purpura","volume":"390","author":"Bendapudi","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2026.109767_bb0210","article-title":"Lenalidomide or thalidomide for transplant-ineligible patients with newly diagnosed multiple myeloma? An overview of systematic reviews","volume":"43","author":"Visacri","year":"2024","journal-title":"Value Health Reg. Issues"},{"issue":"3","key":"10.1016\/j.thromres.2026.109767_bb0215","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00228-021-03216-8","article-title":"Use of ketamine and esketamine for depression: an overview of systematic reviews with meta-analyses","volume":"78","author":"TDM","year":"2022","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.thromres.2026.109767_bb0220","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13643-017-0527-2","article-title":"Systematic review adherence to methodological or reporting quality","volume":"6","author":"Pussegoda","year":"2017","journal-title":"Syst. Rev."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384826001866?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384826001866?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T16:46:08Z","timestamp":1784133968000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384826001866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":44,"alternative-id":["S0049384826001866"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2026.109767","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative effectiveness and safety of rituximab and caplacizumab for immuno-mediated Thrombotic Thrombocytopenic Purpura: an overview of systematic reviews","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2026.109767","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109767"}}